Degarelix
Amber level 0
Brand:
Firmagon ®
Nice TA:
404
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Immune system and Malignant Disease
Background
Degarelix is recommended as an option for treating advanced hormone- dependent prostate cancer in people with spinal metastases, only if the commissioner can achieve at least the same discounted drug cost as that available to the NHS in June 2016. This guidance is not intended to affect the position of patients whose treatment with degarelix was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents: